WuXi AppTec mid-year analysis: Biomedical industry recovery is already underway | Jian Zhi Research
Looking at the mid-year reports from CXO leaders such as WuXi AppTec, IQVIA, and Lonza, hand orders are exceeding expectations. Among them, WuXi AppTec's new hand order amount (excluding COVID-19 business) increased by 33.2%, far beyond the market expectations. The recovery trend of overseas biotech companies has already emerged.
Trending Industry Today: FRONTAGE Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
WuXi AppTec Goes Ex Dividend Tomorrow
Trending Industry Today: TIGERMED Leads Losses In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
Hangzhou Tigermed Consulting Goes Ex Dividend Tomorrow
The total relief rate of Xidacilone race reaches 94%, and sales growth is expected.
On June 4th, Genscript Bio (1548.HK, referred to as "Genscript") announced that its subsidiary, Legend Biotech (LEGN.O), released the results of Phase 2 CARTITUDE-2 (Siltuximab) Cohort D study for the treatment of multiple myeloma patients for the first time at the ASCO Annual Meeting.